|
|
|
|
|
| A correlation study of lipoprotein phospholipase A2 and acute cardio- cerebrovascular diseases |
| SHENG Chang-hong, ZHI Ji-xin |
| The Fourth Clinical Medical College, Harbin Medical University, Harbin 150001, China |
|
|
|
|
Abstract Lipoprotein phospholipase A2 (Lp-PLA2), also known as the plasma platelet activating factor acetyl hydrolase, is mainly produced and secreted by macrophages. About 70% of the Lp-PLA2 in plasma combined with low density lipoprotein (LDL), Lp-PLA2 as a recent new finding of vascular inflammatory reaction substance may be directly participate in the formation of atherosclerotic plaque, the loss of stability and rupture, eventually leading to acute cardiovascular risk events occur.Compared with hypersensitive c-reactive protein (hs-CRP), Lp-PLA2 is a more specific marker of atherosclerosis. Genetic factors, environmental factors, statins and selective Lp-PLA2 inhibitors also have great influences on the lipoprotein level of phospholipase A2-(Lp-PLA2). We believe that by the future investigations of Lp- PLA2, it will provide a new and more effective treatment for the prevention and treatment of atherosclerosis disease; Lp-PLA2 can accurately and timely reflect the severity of the vascular inflammation, prevent the occurrence of acute cardio-cerebrovascular events.
|
|
Received: 26 November 2015
|
|
Corresponding Authors:
ZHI Ji-xin, E-mail: zhijixin23@163.com
|
|
|
|
| [1] Kleber ME，Siekmeier R，Delgado G，et al. C- reactive protein and lipoprotein-associated phospholipase A2 in smokers and nonsmokers of the Ludwigshafen Risk and Cardiovascular Health study[J]. Adv Exp Med Biol，2015，832:15-23.
[2] Wang Y，Zhang J，Qian Y，et al. Association of Lp-PLA2 Mass and Aysmptomatic Intracranial and Extracranial Arterial Stenosis in Hypertension Patients[J]. PLoS One，2015，10（6）: e0 130 473.
[3] Garg S，Madhu SV，Suneja S. Lipoprotein associated phospholipase A2 activity & its correlation with oxidized LDL & glycaemic status in early stages of type- 2 diabetes mellitus[J]. Indian J Med Res，2015，141（1）:107-114.
[4] da Silva IT，de Almeida-Pititto ，Ferreira SR. Reassessing lipid metabolism and its potentialities in the prediction of cardiovascular risk[J]. Arch Endocrinol Metab，2015，59（2）:171-180.
[5] 周国庆，曹勇军，赵和庆. 脂蛋白相关磷脂酶A2：一种独立血管 风险预测因子和治疗新靶点[J]. 国际脑血管病杂志，2010，18（9）: 702-705.
[6] Tsimikas S，Tsironis LD，Tselepis AD. New insights into the role of lipoprotein（a）-associated lipoprotein-associated phospholipase A2 in atherosclerosis and cardiovascular disease[J]. Arterioscler Thromb Vasc Biol，2007，27（10）:2094-2099.
[7] Mahalka AK，Kinnunen PK. Class specific peptide inhibitors for secretory phospholipases A2[J]. Biochem Biophys Res Commun，2013，436（2）:349-353.
[8] 何建新，徐丹苹. 磷脂酶Ａ２及脂蛋白相关磷脂酶Ａ２与动脉粥样硬化相关疾病的研究进展[J]. 实用医学杂志，2014，30（7）:1170-1171.
[9] 何德化，李卫华. 脂蛋白相关磷脂酶A2 与冠心病的相关性研究进展[J]. 心血管病学进展，2008，29（1）:57-60.
[10] 刘甲兴，郑兴，秦永文，等. 脂蛋白相关性磷脂酶A2 活性能反映冠状动脉粥样硬化病变程度[J]. 第二军医大学学报，2006，27（4）:391-395.
[11] 钟萍，吴丹红，吴计划，等. 血清脂蛋白相关磷脂酶A2 和超敏C-反应蛋白水平与大动脉粥样硬化性脑梗死关系的临床研究[J].中华临床医师杂志，2012，6（4）:924-927.
[12] Acevedo M，Varleta P，Kramer V，et al. Comparison of Lipoprotein-Associated Phospholipase A2 and High Sensitive C-Reactive Protein as Determinants of Metabolic Syndrome in Subjects without Coronary Heart Disease: In Search of the Best Predictor[J]. Int J En⁃docrinol，2015，2015:934 681.
[13] Corson M，Jones PH，Davidson MH. ，et al. Review of the evidence for the clinical utility of lipoprotein- associated phospholipase A2 as a cardiovascular risk marker[J]. Am J Cardiol，2008，101（12A）: 41F-50F.
[14] Toth PP，McCullough PA，Wegner MS，et al. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker[J]. Expert Rev Cardiovasc Ther ，2010，8（3）:425-438.
[15] 郑永红，鹿秀霞，陈德伟. 脂蛋白相关性磷脂酶A2 与冠状动脉病变程度及心功能变化的关系[J]. 中国全科医学，2015，20:2398-2401.
[16] 朱雁洲，陈良龙，罗育坤，等. 脂蛋白相关磷脂酶A2 与血管内超声虚拟组织学斑块特征的关系及临床意义[J]. 临床心血管病杂志，2010，26（4）:287-290.
[17] 赵林，张宇晨，玉献鹏，等. 临床SYNTAX 积分和SYNTAX 积分预测复杂冠状动脉性心脏病患者经皮冠状动脉介入治疗预后的对比研究[J]. 新乡医学院学报，2012，29（10）:780-783.
[18] 陈仁玉，王惠娟，于慧丹，等. 人血浆脂蛋白相关磷脂酶A2 与缺血性脑血管病的关系[J]. 脑与神经疾病杂志，2014，22（2）:109-113.
[19] 康建华，杨立顺，袁海生，等. 血浆Lp-PLA2、HCY、血脂水平预测急性脑梗死的价值[J]. 山东医药，2014，45:62-64.
[20] 王少纲. 脂蛋白相关磷脂酶A2 与急性脑梗死的关系[J]. 中国老年学杂志，2013，33（15）:3586-3588.
[21] 史树海，牛建平，王颖慧，等. 磷脂酶A2 与溶血磷脂酸在大鼠脑缺血性损伤后的表达及相互关系研究[J]. 内蒙古医学杂志，2009，41（5）:516-518.
[22] Rosenson RS，Stafforini DM . Modulation of oxidative stress，inflammation，and atherosclerosis by lipoprotein- associated phospholipase A2[J]. J Lipid Res，2012，53（9）:1767-1782.
[23] Kom GD，Schwedhelm E，Maas R，et al. Impact of atorvastatin treatment on platelet- activating factor acetylhydrolase and 15- F（2trans）- isoprostane in hypercholes- terolaemic patients[J]. Br JClin Pharmacol，2007 ，63（6）: 672-679.
[24] 赵娜娜，洪梅，鲁翔，等. 脂蛋白磷脂酶A2 基因I198T 和R92H多态性与中国汉族人群冠心病的相关性[J]. 南京医科大学学报（自然科学版），2013，1:73-77.
[25] Sun GY，Xu J，Jensen MD，et al. Phospholipase A2 in the central nervous system: implications for neurodegenerative diseases[J]. J Lipid Res，2004，45（2）:205-213.
[26] Quach ND，Arnold RD，Cummings BS. Secretory phospholipase A2 enzymes as pharmacological targets for treatment of disease[J].Biochem Pharmacol，2014，90（4）:338-348. |
|
|
|
Address: 1 North 2nd Street,
Zhongguancun, 
